Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.80 |
| ▸ | HTR7 | P34969 | 2/20 | 0.80 |
| ▸ | DRD3 | P35462 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7983132 | 0.89 | HTR7 (1.00) | HTR1AHTR7DRD3ALDH1A1LMNA | |
| SCHEMBL7983795 | 0.86 | HTR7 (0.94) | HTR1AHTR7DRD3ALDH1A1LMNA | |
| SCHEMBL14028451 | 0.84 | HTR1A (0.79) | HTR1ADRD3DRD2MAOB | |
| SCHEMBL6790333 | 0.83 | TDP1 (0.71) | MAPT | |
| SCHEMBL3440240 | 0.81 | MAOB (0.73) | HTR1ADRD2MAOB | |
| SCHEMBL8862878 | 0.81 | TDP1 (0.75) | — | |
| SCHEMBL8862728 | 0.81 | TDP1 (0.75) | — | |
| SCHEMBL6777483 | 0.81 | TDP1 (0.75) | — | |
| SCHEMBL2604742 | 0.81 | TDP1 (0.75) | — | |
| SCHEMBL8863154 | 0.81 | TDP1 (0.75) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | FLORIDA A&M UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | FLORIDA A&M UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | FLORIDA A&M UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | NTSR2, HTR3B, NTSR1 | HTR1A 28/4885HTR7 21/4885DRD3 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.